Highlights

The Indian Pharmaceutical Market grew by 12.1% in May 2026.
Chronic therapies hit a series-high growth of 14.6%.
Broad-based demand across therapy areas continues.

Latest news

Crude may stay capped near $80 if US-Iran truce holds, Hormuz fully reopens: Expert

Crude may stay capped near $80 if US-Iran truce holds, Hormuz fully reopens: Expert

Fahadh Faasil to lead two Malayalam films, teams up with Jacob Babu and Panorama Studios

Fahadh Faasil to lead two Malayalam films, teams up with Jacob Babu and Panorama Studios

Mumbai Police to Receive Monsoon Protection Across Seven Police Stations: Lions Club of Mumbai SOL and RASYS Unite in Tribute to Frontline Heroes

Mumbai Police to Receive Monsoon Protection Across Seven Police Stations: Lions Club of Mumbai SOL and RASYS Unite in Tribute to Frontline Heroes

India-Monaco set to deepen economic ties across key sectors: Piyush Goyal

India-Monaco set to deepen economic ties across key sectors: Piyush Goyal

Centre For Sight Introduces WaveLight Plus InnovEyes for Advanced Personalised Vision Correction

Centre For Sight Introduces WaveLight Plus InnovEyes for Advanced Personalised Vision Correction

Snow Blush Backpack Headlines BGMI's June 17 Redeem Code Release

Snow Blush Backpack Headlines BGMI's June 17 Redeem Code Release

Kaynes Technology eyes Japanese chipmakers with new semiconductor push: Report

Kaynes Technology eyes Japanese chipmakers with new semiconductor push: Report

Transforming Spaces into Luxurious Masterpieces: The RHS Interior Story

Transforming Spaces into Luxurious Masterpieces: The RHS Interior Story

Indian pharma market's double-digit growth momentum is likely to continue further: Equirus

The Indian Pharmaceutical Market experienced a 12.1% growth in May 2026, driven by increased demand across chronic and acute therapies. Key therapies showed double-digit growth, indicating a universal expansion trend.

Indian pharma market's double-digit growth momentum is likely to continue further: Equirus

New Delhi, [India] June 17 (ANI): The Indian Pharmaceutical Market (IPM) is expected to maintain its double-digit growth trajectory, driven by strong volume growth and broad-based demand across therapies, according to a report by brokerage firm Equirus.
The brokerage described May's performance as one of the strongest demand trends in recent years, with both chronic and acute therapies witnessing robust growth.
According to the report, the IPM "posted monthly growth of 12.1 per cent in May'26, marking the sixth consecutive month of double-digit expansion - the most sustained high-growth run in over two years."
On a moving annual total basis, the market grew 10.7 per cent, supported by a balanced contribution from "Volume (+3.2 per cent), Price (+4.6 per cent) and NI (+3.0 per cent), confirming the expansion is broad-based."
Equirus said chronic therapies remained a key growth driver, noting that "chronic growth has hit a series-high 14.6 per cent", raising the segment's share in the market to 40.6 per cent.
The report also highlighted improving demand in acute therapies. It said acute growth reached "a series-high 8.3 per cent", indicating that the market's expansion is being supported by both major segments.
Demand remained strong across therapy categories. Equirus noted that "May data underscored an unusually broad-based demand environment, with nine of the ten key therapies growing in double digits."
Cardiac and anti-diabetic therapies continued to lead growth, while respiratory therapies recorded a strong rebound. Even anti-infectives, which remained the weakest segment, showed signs of recovery.
On growth drivers, Equirus said, "Volume growth accelerated to 3.2 per cent," reflecting a sustained improvement in prescription volumes. It added that new introductions contributed 3.0 per cent growth, "the highest in the five-period series", aided by successful chronic therapy launches.
The brokerage added that the IPM's current growth momentum is now "genuinely broad-based", with strong demand trends likely to support continued expansion in the coming months. (ANI)

(This article was generated from news agency ANI without modifications to the text.)

ADVERTISEMENT

Up Next

Indian pharma market's double-digit growth momentum is likely to continue further: Equirus

Indian pharma market's double-digit growth momentum is likely to continue further: Equirus

Honda Activa 6G: Everything You Need to Know Before Buying

Honda Activa 6G: Everything You Need to Know Before Buying

How much does a ULIP plan really cost? A break-down of all charges

How much does a ULIP plan really cost? A break-down of all charges

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

Reliance denies buying Iranian oil amid US sanctions waiver

Reliance denies buying Iranian oil amid US sanctions waiver

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

ADVERTISEMENT

editorji-whatsApp

More videos

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

Govt announces seven measures to help boost exports

Govt announces seven measures to help boost exports

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI pauses rate cuts, retains interest rate at 5.25 pc

RBI pauses rate cuts, retains interest rate at 5.25 pc

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

UPI transactions hit record high of Rs 230 lakh crore in 2025-26 till Dec: Govt

UPI transactions hit record high of Rs 230 lakh crore in 2025-26 till Dec: Govt

Explained: India-US trade deal, tariffs and trade benefits

Explained: India-US trade deal, tariffs and trade benefits

Editorji Technologies Pvt. Ltd. © 2022 All Rights Reserved.